Seeking Alpha
Seeking Alpha Portfolio App for iPad
Finance
(1)
Market Currents

Oncothyreon's (ONTY -12%) after Martin Shkreli questions the benefits of the company's lung...

  • Monday, July 25, 2011, 12:20 PM ET
    Oncothyreon's (ONTY -12%) after Martin Shkreli questions the benefits of the company's lung cancer drug Stimuvax. He asserts the drug is poorly designed, fails to improve lung cancer survival and is not likely to pass its phase III testing trials. 
Track new comments on this story

This news story has 5 comments:

  • Still another false and misleading 'opinion piece' written by a short hack. There are few verifiable facts, and a majority of the comments/opinions are proven to be false.
    25 Jul 2011, 12:36 PM Reply Like
  • This site is an enabler of illegal stock manipulatr IMO.
    25 Jul 2011, 07:24 PM Reply Like
  • I'm glad I bought some ONCY calls last Friday, after reading Redplate's comments and reviewing the following link -- sites.google.com/site/...
    31 Jul 2011, 04:07 PM Reply Like
  • if you bought ONCY it was the wrong stock dude. At least get the trade symbol right.
    red
    1 Aug 2011, 09:57 AM Reply Like
  • It was indeed ONTY. I should have re-read before hitting send. My bad.
    2 Aug 2011, 08:55 AM Reply Like
Other date
DJIA (DIA) S&P 500 (SPY)